Axon Enterprise, the maker of the Taser and a fast growing suite of policing hardware and software, jumped into headlines after disclosures showed President Donald Trump bought a sizable stake in the company earlier this year, just weeks before a federal agency sought thousands of new stun guns built to specs that closely match Axon's own product.
Shares of Axon (NASDAQ:AXON) closed at 576.81 dollars, down 3.83% on the day, giving the company a market capitalization of 48.35 billion dollars. The stock has traded between 366.00 and 665.07 dollars over the past year, and it has climbed sharply in recent sessions as the political angle to its federal business drew fresh attention.
| Price | 576.81 USD |
|---|---|
| Day change | -22.96 (-3.83%) |
| 52-week range | 366.0 – 665.07 |
| Market cap | $48.35B |
| RSI (14) | 63.35 |
| Volume | 617,162 |
What Triggered the Scrutiny
Trump purchased between 1 million and 5 million dollars worth of Axon shares on February 10, according to a disclosure filed in May with the Office of Government Ethics. Two weeks later, on February 24, Immigration and Customs Enforcement posted a notice seeking roughly 17,800 new tasers, unlimited cartridges and training, under a proposed five year contract worth about 220 million dollars. That contract has not been awarded yet.
The notice does not mention Axon by name, but three policing experts and procurement reviewers told reporters the listed specifications, a 45 foot range and ten targeted probes among them, point only to Axon's Taser 10. Axon already accounts for roughly 90% of taser sales in the United States, according to investment firm Brown Advisory. If the ICE order goes through as proposed, it would more than quadruple the agency's current stockpile of about 4,300 devices.
The White House says Trump's holdings sit in a trust overseen by his children and run by independent managers. Spokesperson Anna Kelly said there are no conflicts of interest and dismissed the scrutiny as a tired narrative. Jordan Libowitz of Citizens for Responsibility and Ethics in Washington took a different view, saying the concern is that a sitting president bought into a company whose business could expand alongside his own administration's immigration enforcement push.
Axon's Valuation, Momentum and Yield
Axon carries a price to earnings ratio of roughly 116, reflecting a stock priced for continued rapid expansion rather than current profits. Earnings per share sit near 4.97 dollars. The stock pays no dividend, so the entire investment case rests on growth and eventual margin expansion rather than income.
The relative strength index reads 63.35, a level that signals firm buying interest without yet tipping into clearly overbought territory. That momentum shows up in the stock's move over the past two trading sessions, up more than 20% since the ICE story broke.
The bull case centers on Axon's ninth consecutive quarter of revenue growth above 30%, a streak that predates any political drama, plus a 370 million dollar Department of Homeland Security contract for body cameras and software signed in 2023, of which only about 67.5 million dollars has been drawn down so far. Axon President Josh Isner told investors at the William Blair Growth Stock Conference on June 4 that federal law enforcement is a stronger market for the company than defense work, and that selling new products into existing customer relationships remains the core growth lever.
The bear case is more about optics than fundamentals. No evidence has surfaced that Trump knew about the coming ICE request or that ICE knew of his stake, but the timing has drawn attention from ethics watchdogs and could invite continued political and regulatory scrutiny that has little to do with Axon's underlying sales or margins.
How Much Federal Business Is Actually Locked In
The ICE taser contract remains unawarded, and the DHS body camera deal is still far from fully spent down. Whether these federal opportunities convert into booked revenue, and how much attention the ownership question draws from Congress or ethics offices, remains an open question tied to procurement timelines rather than Axon's quarterly results.